Vaccines
20 March 2017
GeoVax Reports Promising Results for Zika Vaccine13 March 2017
Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer9 March 2017
CyTuVax starts its Phase 2 BE RESPONDER! study28 February 2017
Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease28 February 2017
Inovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy23 February 2017
Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases22 February 2017
ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease22 February 2017
hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate21 February 2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data in Relapsing Multiple Sclerosis15 February 2017
TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Review14 February 2017
Allergy Therapeutics PLC Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval6 February 2017
Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer2 February 2017
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients24 January 2017
GeoVax Announces Initiation of HIV Human Clinical TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports